Scholarlink

<p>High shear wet granulation (HSWG) is a conventional and widely used pharmaceutical drug product manufacturing process. Proper process control of the HSWG is crucial for ensuring the quality of granulation and, consequently, the final drug product. To demonstrate the adequacy of a proposed HSWG commercial process, the control of critical process parameters should be well established based on sufficient development data and scientific rationale. At the U.S. Food and Drug Administration (FDA), during the Chemistry, Manufacturing and Controls (CMC) assessment of original drug applications, deficiencies related to manufacturing process controls have been often found to be one of the causes of extended application review time or cycle numbers. In this paper, we have analyzed deficiencies from the manufacturing assessment of applications from 2017 to 2022 in which HSWG was used to produce oral solid dosage form drug products. The results revealed that the most frequently occurring deficiencies in the control of the HSWG process are related to lack of controls for granulation end point, granulation fluid level, granulation fluid addition rate, wet massing time, and process scale up strategy. This paper discusses the impact of these deficiencies on HSWG and final drug product quality along with recommendations for improvement of process controls.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High Shear Wet Granulation Process Common Deficiencies Observed in Recently Submitted New and Abbreviated Drug Applications

  • 期刊论文

  • 发表日期：

    2026年1月23日

查看全文
  • Lixia Cai,
  • Haitao Li,
  • Hang Guo,
  • Steve Y. Rhieu,
  • Zhouxi Wang,
  • Feiyan Jin,
  • Qiang Han

摘要

High shear wet granulation (HSWG) is a conventional and widely used pharmaceutical drug product manufacturing process. Proper process control of the HSWG is crucial for ensuring the quality of granulation and, consequently, the final drug product. To demonstrate the adequacy of a proposed HSWG commercial process, the control of critical process parameters should be well established based on sufficient development data and scientific rationale. At the U.S. Food and Drug Administration (FDA), during the Chemistry, Manufacturing and Controls (CMC) assessment of original drug applications, deficiencies related to manufacturing process controls have been often found to be one of the causes of extended application review time or cycle numbers. In this paper, we have analyzed deficiencies from the manufacturing assessment of applications from 2017 to 2022 in which HSWG was used to produce oral solid dosage form drug products. The results revealed that the most frequently occurring deficiencies in the control of the HSWG process are related to lack of controls for granulation end point, granulation fluid level, granulation fluid addition rate, wet massing time, and process scale up strategy. This paper discusses the impact of these deficiencies on HSWG and final drug product quality along with recommendations for improvement of process controls.